Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial

• Prif Awduron: Laura E. Flores (Awdur), Kristen M. Beavers (Awdur), Daniel P. Beavers (Awdur), Katelyn A. Greene (Awdur), Diana A. Madrid (Awdur), Ryan M. Miller (Awdur), Jamy D. Ard (Awdur), Laura D. Bilek (Awdur), Ashley A. Weaver (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2023-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Background Despite robust weight loss and cardiometabolic benefit, lean mass loss following sleeve gastrectomy (SG) confers health risk. Bisphosphonates are a potential therapeutic agent for lean mass maintenance. Thus, our objective was to explore the effect of 6 months of risedronate (vs....